CJC-1295 Research Studies: Publication Lineage and Endpoint Differences

CJC-1295 research studies are easier to interpret when their publication lineage and endpoints are kept visible. PMID 16352683 reports two randomized, placebo-controlled, double-blind ascending-dose trials that examined pharmacokinetics, pharmacodynamics, and safety. PMID 17018654 reports a 12-hour, 20-minute sampling study focused on GH pulsatility after a single injection. The cited records do not establish whether the participant groups overlapped, so that relationship is not established from the cited records.

Publication lineage map

The first record (PMID 16352683) is a two-trial programme conducted at two investigational sites in healthy adults aged 21-61 years. Its stated durations were 28 and 49 days. The later record (PMID 17018654) is a separate report of overnight GH sampling in healthy men aged 20-40 years before and one week after an injection. Both papers concern a long-acting GHRH analogue, but they answer different measurement questions and should not be treated as duplicate counts or as one continuous cohort without supporting documentation.

Publication metadata show different author lists: Teichman and colleagues for PMID 16352683, and Ionescu and Frohman for PMID 17018654. Shared subject identity, recruitment sequence, and protocol linkage are not stated in the abstracts. A reviewer should therefore preserve each paper as its own record and flag cohort linkage as unresolved.

Protocol ledger: the two ascending-dose trials

In PMID 16352683, CJC-1295 or placebo was administered subcutaneously. The first trial used one of four ascending single doses; the second used two or three weekly or biweekly doses. The abstract does not list every dose value for the four single-dose groups, so this article does not infer them. It does report that 30 or 60 microg/kg were among the doses discussed in the authors’ tolerability conclusion.

The main outcome measures were peak concentrations and area under the curve for GH and IGF-I, together with standard pharmacokinetic parameters for CJC-1295. After one injection, mean plasma GH increased by 2- to 10-fold for six days or more, while mean IGF-I increased by 1.5- to 3-fold for nine to eleven days. The estimated CJC-1295 half-life was 5.8-8.1 days. After multiple doses, mean IGF-I remained above baseline for up to 28 days. No serious adverse reactions were reported in the abstract.

The authors concluded that subcutaneous CJC-1295 produced sustained, dose-dependent GH and IGF-I increases in the healthy-adult study population and described the tested treatment as relatively well tolerated, particularly at 30 or 60 microg/kg. That is the authors’ conclusion for their trial design; it is not a human-use dose recommendation, product claim, or general safety guarantee. Primary record: PMID 16352683.

Endpoint ledger: the 12-hour pulse analysis

PMID 17018654 asked a narrower physiological question: whether GH pulsatility was preserved after CJC-1295 and which secretion parameters related to IGF-I change. Healthy men aged 20-40 years underwent blood sampling every 20 minutes during an overnight 12-hour period before and one week after a single subcutaneous injection of 60 or 90 microg/kg.

The study reports increased GH secretion with preserved pulsatility. Pulse frequency and pulse magnitude were not significantly altered. Basal (trough) GH increased 7.5-fold (P < 0.0001), mean GH increased 46% (P < 0.01), and IGF-I increased 45% (P < 0.001). No significant response difference was observed between the two tested dose groups, and IGF-I increases did not correlate with the measured GH secretion parameters. The authors concluded that higher trough and mean GH, rather than altered pulse frequency or magnitude, accompanied the IGF-I increase in this study. Primary record: PMID 17018654.

What the two designs measure

Duration is not pulsatility

The 5.8-8.1-day half-life estimate and multi-day GH/IGF-I elevations in PMID 16352683 describe concentration and response duration under its PK/PD design. The 12-hour sampling in PMID 17018654 describes the pattern of GH secretion at two time points. A longer apparent exposure does not by itself specify pulse frequency, pulse magnitude, or trough level. Conversely, preserved pulsatility in an overnight record does not reproduce the multi-week PK estimates from the other paper.

What may be shared and what cannot be inferred

• Both records can be cited as human CJC-1295 research with source-attributed conditions and endpoints.
• The two papers can be compared at the level of question and measurement type: PK/PD and safety versus pulse-pattern analysis.
• They should not be combined into one participant count or one dose-response dataset; cohort overlap is not established from the cited records.
• The reported doses, routes, durations, and results cannot be converted into administration instructions, treatment claims, or safety guarantees.
• Neither paper establishes that a commercial or catalogue material is the tested study material.

Relation to material records

The public CJC-1295 and Ipamorelin Material-Identity Guide addresses catalogue terminology and record boundaries. It is not a substitute for either primary study. Keep each paper’s population, dose, sampling schedule, endpoint, statistical result, and limitation attached to its citation, and keep product or batch records in separate files.

References

• Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. PMID 16352683.
• Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. PMID 17018654.

Research scope: This summary reports study details from the cited source and does not provide medical, veterinary, dosing, administration, safety, or treatment guidance. It does not represent a product-use recommendation.